343 related articles for article (PubMed ID: 6537698)
1. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
Rezzano S; Armas JA; Moreno G; Scorza JV
Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
[No Abstract] [Full Text] [Related]
2. [Experimental chemotherapy in hamsters, using paromomycin against 2 isolates of Leishmania mexicana and Leishmania braziliensis].
Rezzano S; Moreno G; Scorza JV
Rev Cubana Med Trop; 1982; 34(1):34-45. PubMed ID: 6750713
[No Abstract] [Full Text] [Related]
3. [Effectiveness of paromomycin-I against Leishmania garnhami in heterozygote albino mice].
Rezzano de Raffo S; Moreno G; García J; Scorza JV
Rev Cubana Med Trop; 1985; 37(1):55-65. PubMed ID: 3915382
[No Abstract] [Full Text] [Related]
4. Intralesional glucantime in Leishmania braziliensis braziliensis infections.
Barrios LA; Costa JM; Netto EM; Vexenat CO; Cuba CC; Marsden PD
Trans R Soc Trop Med Hyg; 1986; 80(1):173-4. PubMed ID: 3726989
[No Abstract] [Full Text] [Related]
5. Development of Leishmania (Viannia) panamensis lesions and relationship of numbers of amastigotes to lesion area on antimony-treated and untreated hamsters.
Hanson WL; Chapman WL; Waits VB; Lovelace JK
J Parasitol; 1991 Oct; 77(5):780-3. PubMed ID: 1919929
[TBL] [Abstract][Full Text] [Related]
6. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases.
Costa JM; Marsden PD; Llanos-Cuentas EA; Netto EM; Carvalho EM; Barral A; Rosa AC; Cuba CC; Magalhães AV; Barreto AC
J Trop Med Hyg; 1986 Dec; 89(6):319-23. PubMed ID: 3806749
[TBL] [Abstract][Full Text] [Related]
7. [Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis].
Romero GA; Lessa HA; Macêdo VO; Carvalho EM; Barral A; Magalhães AV; Orge MG; Abreu MV; Marsden PD
Rev Soc Bras Med Trop; 1996; 29(6):557-65. PubMed ID: 9011880
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of human Leishmania braziliensis braziliensis infections.
Llanos Cuentas EA; Cuba CC; Barreto AC; Marsden PD
Trans R Soc Trop Med Hyg; 1984; 78(6):845-6. PubMed ID: 6533860
[No Abstract] [Full Text] [Related]
9. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.
Grogl M; Thomason TN; Franke ED
Am J Trop Med Hyg; 1992 Jul; 47(1):117-26. PubMed ID: 1322070
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime.
Netto EM; Marsden PD; Llanos-Cuentas EA; Costa JM; Cuba CC; Barreto AC; Badaró R; Johnson WD; Jones TC
Trans R Soc Trop Med Hyg; 1990; 84(3):367-70. PubMed ID: 2260171
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of leishmaniasis (author's transl)].
Barabe P
Med Trop (Mars); 1981; 41(6):599-605. PubMed ID: 7339417
[TBL] [Abstract][Full Text] [Related]
13. Retention of antimony in hair during leishmaniasis treatment.
Dorea JG; Merchan-Hamann E; Ryan DE; Holzbecher J
Clin Chim Acta; 1989 Feb; 179(3):341-5. PubMed ID: 2714007
[No Abstract] [Full Text] [Related]
14. Berberine derivatives as antileishmanial drugs.
Vennerstrom JL; Lovelace JK; Waits VB; Hanson WL; Klayman DL
Antimicrob Agents Chemother; 1990 May; 34(5):918-21. PubMed ID: 2360830
[TBL] [Abstract][Full Text] [Related]
15. [Aminosidine in the treatment of mucocutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis].
Romero GA; Lessa HA; Macêdo V; de Carvalho EM; de Magalhães AV; Orge M de la G; de Abreu MV; Marsden PD
Rev Soc Bras Med Trop; 1996; 29(2):215-6. PubMed ID: 8713613
[No Abstract] [Full Text] [Related]
16. Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy.
Avila JL; Biondo F; Monzón H; Convit J
Am J Trop Med Hyg; 1982 Jan; 31(1):53-9. PubMed ID: 7058978
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of cutaneous leishmaniasis with glucantime. Apropos of 9 cases].
Ramos García AN; Pérez Avila J; Pérez Ramos E; Díaz Hernández A; Ruiz Pérez A
Rev Cubana Med Trop; 1984; 36(2):151-9. PubMed ID: 6399595
[No Abstract] [Full Text] [Related]
18. N-methylglucamine antimonate (SbV+): intralesional canine tegumentary leishmaniasis therapy.
Barbosa Santos EG; Marzochi MC; Conceição NF; Brito CM; Barroso JA; Pacheco RS
Parasite; 1998 Jun; 5(2):175-80. PubMed ID: 9754314
[TBL] [Abstract][Full Text] [Related]
19. Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria.
Belazzoug S; Neal RA
Trans R Soc Trop Med Hyg; 1986; 80(4):670-1. PubMed ID: 3544363
[No Abstract] [Full Text] [Related]
20. The fitness of antimony-resistant Leishmania parasites: lessons from the field.
Ait-Oudhia K; Gazanion E; Oury B; Vergnes B; Sereno D
Trends Parasitol; 2011 Apr; 27(4):141-2. PubMed ID: 21216196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
